⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of JNPMEDI and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
JNPMEDI
↗Seoul, South Korea
JNPMEDI is a South Korean healthcare IT and clinical research company that provides a cloud-based, AI-powered platform called 'Maven Clinical Cloud' to digitalize clinical trial operations. The company specializes in decentralized clinical trials (DCTs), offering end-to-end solutions including electronic data capture (EDC), clinical outcome assessment (eCOA), and regulatory consulting to pharmaceutical, biotech, and medical device companies.
Beyond its software platform, JNPMEDI has expanded into professional services, supporting the entire product lifecycle from research and development to commercialization. The company leverages advanced technologies like blockchain and cloud computing to ensure data integrity and operational efficiency, aiming to help clients navigate global regulatory requirements and accelerate time-to-market.
CLASSIFICATION
Company Type:Digital Health
Therapeutic Areas:-
Industry:Digital Health
Sub-Industry:Clinical Research Software (eClinical)
SIZE & FINANCIALS
Employees:51-200
Founded:2020
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$10.3M
Investors:Naver, TBT Partners, AJU IB Investment, Kakao Ventures, Murex Partners, Gentium Partners
0
CORPORATE STRUCTURE
Key Partnerships:Welt (Digital Therapeutics), EverEx (Digital Therapeutics), KoNECT (Korea National Enterprise for Clinical Trials)
COMPETITION
Position:Emerging
Competitors:Lokavant, eClinical Solutions, Clinithink, Medidata
LEADERSHIP
Key Executives:
Kwunho Jeong - CEO
Yoo Soo-hyun - Vice President
LINKS
Website:jnpmedi.com
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with JNPMEDI. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.